Stay updated on Epacadostat + Sirolimus in Advanced Malignancy Clinical Trial
Sign up to get notified when there's something new on the Epacadostat + Sirolimus in Advanced Malignancy Clinical Trial page.

Latest updates to the Epacadostat + Sirolimus in Advanced Malignancy Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe web page has been updated to reflect a new version of the study protocol, including specific details about the dose escalation and expansion cohorts for a clinical trial involving the IDO1 inhibitor epacadostat and sirolimus. Notably, the Principal Investigator has been identified as Chao Huang, MD, from the University of Kansas Medical Center.SummaryDifference55%
- Check19 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check27 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check63 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check77 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check84 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Epacadostat + Sirolimus in Advanced Malignancy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Epacadostat + Sirolimus in Advanced Malignancy Clinical Trial page.